SCHEMBL18946207

SCHEMBL18946207

Cn1cnc2cc(C#C[Si](C)(C)C)cnc21

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.65
DYRK1A Q13627 1/20 0.35
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
YTHDC1 Q96MU7 1/20 0.30
IRAK4 Q9NWZ3 1/20 0.30
CSF1R P07333 1/20 0.30
TNIK Q9UKE5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9903456 0.79 GRM5 (1.00) GRM5TNIK
SCHEMBL24463055 0.77 GRM5 (0.61) GRM5DYRK1AADORA2AADORA1YTHDC1
SCHEMBL27072911 0.77 GRM5 (0.61) GRM5DYRK1AGABRA1GABRG2GABRB3
SCHEMBL9903377 0.76 GRM5 (0.73) GRM5TNIK
SCHEMBL18946091 0.75 GRM5 (0.68) GRM5GABRA1GABRA5
SCHEMBL9903825 0.73 GRM5 (0.72) GRM5
SCHEMBL10238681 0.72 GRM5 (0.50) GRM5DYRK1AADORA2AADORA1YTHDC1
SCHEMBL20641223 0.72 GRM5 (0.51) GRM5DYRK1AGABRA1GABRG2GABRB3
SCHEMBL9994861 0.71 GRM5 (0.43) GRM5GABRA1GABRG2GABRB3GABRA5
SCHEMBL24463610 0.70 KDM4E (0.35) GRM5GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111416154-B Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery 松山湖材料实验室 2021-08-06 CN claimed
CN-111416154-A Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery 松山湖材料实验室 2020-07-14 CN claimed
CN-116057045-A Fibroblast growth factor receptor kinase inhibitors 金耐特生物制药公司 2023-05-02 CN disclosed
EP-4161656-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES Kinnate Biopharma Inc. (US) 2023-04-12 EP disclosed
US-11345681-B1 Inhibitors of fibroblast growth factor receptor kinases KINNATE BIOPHARMA INC. (US) 2022-05-31 US disclosed
WO-2017093544-A1 ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS AUSPHERIX LIMITED (GB) 2017-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345681-B1 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 GRM5 2790/4885DYRK1A 967/4885ADORA2A 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.